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No data are available on the role of HER2 overexpression in predicting the efficacy of dose-dense anthracycline-containing adjuvant
chemotherapy in breast cancer patients. We retrospectively evaluated this role in patients enrolled in a phase III study comparing
standard FEC21 (5-fluorouracil, epirubicin, and cyclophosphamide, administered every 3 weeks) vs dose-dense FEC14 (the same
regimen repeated every 2 weeks). HER2 status was determined for 731 of 1214 patients. Statistical analyses were performed to test
for interaction between treatment and HER2 status with respect to event-free survival (EFS) and overall survival (OS); EFS and OS
were compared within each HER2 subgroup and within each treatment arm. Median follow-up was 6.7 years. Among FEC21-treated
patients, both EFS (HR¼2.07; 95% CI 1.27–3.38) and OS (HR¼2.47; 95% CI 1.34–4.57) were significantly worse in HER2þ
patients than in HER2  patients. Among FEC14-treated patients, differences in either EFS (HR¼1.21; 95% CI 0.65–2.24) or OS
(HR¼1.85; 95% CI 0.88–3.89) between HER2þ and HER2  patients were not statistically significant. Interaction analysis suggested
that the use of dose-dense FEC14 might remove the negative prognostic effect of HER2 overexpression on EFS and OS. Our data
suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the
need to confirm this hypothesis in future prospective studies.
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HER-2 overexpression or amplification has been widely studied as
a prognostic and predictive factor in early breast cancer patients
but its role is still controversial (Trock et al, 2000; Ravdin, 2001;
Sledge, 2001; Yamauchi et al, 2001; Goldhirsch et al, 2003). In most
studies, overexpression or amplification of the HER2 gene has
been associated with an adverse clinical outcome (Schnitt, 2001).
With regard to HER2 as a predictive factor, retrospective studies
have suggested that the benefit from anthracycline-containing
chemotherapy might be greater in women whose tumour over-
expresses HER2 (Paik et al, 1998, 2000; Di Leo et al, 2002). Another
important issue is to evaluate if HER2 overexpression is associated
not only with sensitivity to anthracyclines but also to their dose-
intensity and dose-density effect. Results from a retrospective
study suggest that regimens with an increased dose per cycle (dose
intensity) of anthracyclines (Thor et al, 1998) are associated with
an improved outcome only in women with HER2 overexpression.
Recent data showed that anthracycline-containing chemotherapy
with increased dose density (obtained by the administration of
the drugs with a shortened interval), but with the same dose per
cycle and total dose, improves clinical outcome as compared to
conventionally scheduled (every 3 weeks) regimens (Citron et al,
2003; Venturini et al, 2003). However, no data are available on the
potential role of HER2 overexpression in predicting the efficacy
of dose-dense anthracycline-containing chemotherapy. The aim of
this study was to evaluate the prognostic and predictive role of
HER2 overexpression in early breast cancer patients enrolled in a
trial that compared standard vs dose-dense epirubicin-containing
adjuvant chemotherapy.
PATIENTS AND METHODS
The patients evaluated in the present study were a subgroup of the
study population entered into a prospective clinical trial. HER2
status was centrally evaluated in primary breast cancer samples
from patients enrolled in a phase III multicentre study comparing
standard vs dose-dense adjuvant chemotherapy (GONO-MIG-1
study, Gruppo Oncologico Nord-Ovest-Mammella Intergruppo).
The GONO-MIG-1 study was conducted in 22 Italian centres
enrolling 1214 patients from 1992 to 1996. Women (age p70
years) with histologically confirmed breast cancer who had
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sundergone radical mastectomy or breast-conserving surgery plus
full ipsilateral axillary node dissection were eligible for enrolment
in the study if they had no more than 10 involved axillary
nodes or were node negative but had a high risk of recurrence.
High risk was defined as the presence of one or more of the
following characteristics: age p35 years, negative oestrogen (ER)
and progesterone receptor (PgR) status, tumour size X2cm,
poor histological grade, high proliferative rate determined by
[
3H]thymidine labelling index, or by S-phase determination by
flow cytometry. Patients were randomly assigned to receive either
six courses of FEC21 (5-fluorouracil 600mgm
 2, epirubicin
60mgm
 2, and cyclophosphamide 600mgm
 2 intravenously on
day 1, repeated every 3 weeks) or six courses of dose-dense FEC14
(the same drugs at the same doses of FEC21, repeated every 2
weeks), with the support of filgrastim, a granulocyte colony-
stimulating factor (G-CSF). Granulocyte colony-stimulating factor
was subcutaneously self-administered by patients, at a dose of
5mgkg
 1day
 1, on days 4–11. Patients with ER- and/or PgR-
positive tumours received tamoxifen 20mgday
 1 for 5 years.
Postoperative regional radiotherapy limited to the remaining
breast was given to patients who had received conservative
surgery.
Tumour sample collection
All 22 participating centres were invited to participate in this study
on the role of HER2 status (HER2 study) and 18 centres accepted.
Each centre was provided with a list of all patients entered into the
clinical study. Each centre sent one paraffin-embedded sample of
the primary tumour to the Pathology unit of the National Cancer
Research Institute of Genoa, Italy. Once samples were received,
they were classified and stored at room temperature until the
HER2 analysis was carried out.
HER2 evaluation
Immunohistochemical analysis was performed using monoclonal
antibody CB-11 (Biogenex, San Ramon, CA, USA). Sections (3-mm-
thick) from formalin-fixed, paraffin-embedded tissue were cut
and mounted on positively charged slides. Tissue sections were
deparaffinised and rehydrated in graded alcohol. No antigen
retrieval procedure was used. Slides were placed in TBS (0.05 M
Tris/HCl; 0.15 M NaCl; pH 7.6) and endogenous peroxidase activity
was blocked by a 5min treatment with 3% hydrogen peroxide
solution. Blocking solution was applied for 20min, followed by
incubation with the primary antibody (1:10 dilution TBS) for
30min. Tissue sections received a 5min TBS rinse before the
application of biotinylate secondary antibody (1:200 dilution TBS)
for 30min and then a second 5min TBS rinse. Antibody was
localised using the streptavidin biotin immunoperoxidase (Dako,
Dakocytomation, Milan, Italy; 1:10 dilution TBS), and 30-3
diaminobenzidine was used to visualise the chromogen. Slides
were counterstained in Mayer haematoxylin, dehydrated, and
mounted. For each run, a composite slide of three formalin-fixed
human breast carcinoma cell lines representing different levels
of HER2 protein expression (MDA-231¼0; MDA-175¼1þ; and
SKBR¼3þ) was used as control. In addition, an overexpressing
HER2 tissue section of breast cancer was used as positive and
negative control. Negative control was made by substituting the
HER2 primary antibody with normal rabbit serum. When both
carcinoma in situ and invasive carcinoma were present in the same
section, only the invasive component was scored. For the
determination of HER2 protein overexpression, only the mem-
brane staining intensity and pattern were evaluated as follows: no
staining or membrane staining in less than 10% of the tumour:
score 0; a faint/barely perceptible membrane staining in more than
10% of the tumour cells, stained only in part of their membrane:
score 1þ; a weak to moderate complete membrane staining in
more than 10% of the tumour cells: score 2þ; a strong complete
membrane staining in more than 10% of tumour cells: score 3þ.
In this study, patients were considered HER2 positive
(HER2þ), that is, with overexpression of HER2, if it was scored
as 3þ; patients with HER2 scored as 0, 1þ,2þ were considered
HER2 negative (HER2 ). The cutoff of 3þ was chosen before
inspection of clinical results in order to consider as positive only
tumours with unequivocal HER2 overexpression (Zarbo and
Hammond, 2003).
The same pathologist, who was blinded to both treatment
assignment and clinical outcome, scored all slides.
Statistical methods
Overall survival (OS) was estimated from the date of randomisa-
tion to the date of last contact or death from any cause. Event-free
survival (EFS) was defined as the interval that had elapsed between
the date of randomisation and the date of local relapse, distant
relapse, second breast primary, or death from any cause,
whichever occurred first.
All selected patients, regardless of eligibility or of compliance to
the assigned treatment, were considered in the arm they were
assigned at randomisation in the original study and there were no
further exclusions.
The prognostic role of HER2 status on EFS and OS was assessed
by fitting a multivariate proportional hazard model to the data.
The following variables were initially included in the model:
Table 1 Patient characteristics by HER-2 availability
All patients HER2 status HER2 status
(n¼1214)
Available
(n¼731)
Not available
(n¼483)
No. % No. % No. %
Age (years)
Median (range) 54 (25–70) 54 (25–70) 54 (26–70)
o50 470 38.7 262 35.8 208 43.1
50–59 425 35.0 253 34.7 172 35.6
459 319 26.3 216 29.5 103 21.3
Tumour size
pT1 598 49.2 344 47.1 254 52.6
pT2 542 44.6 338 46.2 204 42.2
pT3-4 60 5.0 39 5.3 21 4.4
Unknown 14 1.2 10 1.4 4 0.8
Nodal status
Negative 431 35.5 275 37.6 156 32.3
Positive 783 64.5 456 62.3 327 67.7
Grading
G1 63 5.1 44 6.0 19 3.9
G2 603 49.7 374 51.2 229 47.4
G3 405 33.4 234 32.0 171 35.4
Unknown 143 11.8 79 10.8 64 13.3
ER status
Negative 500 41.1 318 43.5 182 38.1
Positive 628 51.8 392 53.6 236 49.4
Unknown 86 7.1 21 2.9 65 13.5
PgR status
Negative 580 47.7 366 50.1 214 44.3
Positive 476 39.2 304 41.6 172 35.6
Unknown 158 13.1 61 8.3 97 20.1
ER¼oestrogen receptor; PgR¼progesterone receptor.
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streatment assigned at randomisation, age, menopausal status,
tumour size, nodal status, grading, ER status, PgR status,
proliferative activity, and HER2 status. The final model was
obtained by means of a step-down procedure based on the
likelihood ratio test. In order to retain in the final model as many
potential confounding factors as possible, it was decided, prior to
data analysis, to use relaxed significance levels (i.e. Po0.15). The
heterogeneity of the effect of the adjuvant regimen (dose dense vs
standard) according to HER2 status was investigated by including
in each final model (for EFS and OS) an interaction term
representing the modification of the effect of dose-dense therapy
in HER2þ patients. For descriptive purposes, OS and EFS in
patients assigned to dose-dense or standard adjuvant therapy were
also compared separately within each HER2 subgroup. Kaplan–
Meier estimates and plots were used in all univariate analyses.
RESULTS
Results regarding all patients (n¼1214) enrolled in the clinical
trial GONO-MIG1 have been recently presented (Venturini et al,
2003). At a median follow-up of 6.7 years, a 19% reduction in the
hazard of death was observed in favour of the FEC14 arm.
Collection of tumour samples
Four out of 22 centres involved in the GONO-MIG1 study, which
had enrolled 164 cases, chose not to participate in the HER2 study.
The 18 centres participating in the HER2 study enrolled 1050
patients in the GONO-MIG1 study.
A total of 731 paraffin-embedded samples of primary tumours
suitable for HER2 analysis were collected between December 1998
and February 2000, corresponding to 60% of the overall trial
population (1214 patients) and to 70% of the patients recruited in
centres participating in this study (1050 patients). Reasons for the
lack of HER2 evaluation in 319 cases were the following: tumour
specimen not available (294 cases); tumour specimen inadequate
(23 cases); unknown (two cases).
Study population
To explore if the subgroup of patients evaluated in the HER2 study
was representative of the whole population entered in the clinical
trial, the main patient and tumour characteristics in this subgroup
(731 cases) were compared with those of the subgroup without
HER2 assessment (483 cases). No major difference was observed
between the two subgroups (Table 1). Among the 731 patients
evaluated in this study, no differences were observed between
the two treatment arms. Tumour characteristics and chemotherapy
regimen by HER2 status are shown in Table 2. HER2 was over-
expressed, that is, 3þ (HER2þ), in 13.5% of FEC14-treated
patients and in 14.7% of FEC21-treated patients. A negative
hormone receptor status (i.e. both ER and PgR negative) was
observed more frequently in tumours overexpressing HER2 (62%)
than in HER2-negative (32.5%) tumours.
HER2 overexpression as a prognostic factor
HER2 overexpression was associated with a poor prognosis. Event-
free survival was significantly worse in HER2þ patients than in
HER2  patients. At a median follow-up of 6.7 years, 33
recurrences occurred among the 103 HER2þ patients, compared
to 137 recurrences among the 628 HER2  patients for an actuarial
Table 2 Treatment arm and tumour characteristics by HER2 status
HER2¼0( n¼542) HER2¼1+ (n¼39) HER2¼2+ (n¼47) HER2¼3+ (n¼103)
No. % No. % No. % No. %
Treatment arm
FEC14 277 51.1 19 48.7 24 51.1 50 48.5
FEC21 265 48.9 20 51.3 23 48.9 53 51.5
Tumour size
pT1 261 48.2 15 38.5 25 53.2 43 41.7
pT2 246 45.4 19 48.7 17 36.2 56 54.4
pT3–4 30 5.5 3 7.7 4 8.6 2 2.0
Unknown 5 0.9 2 5.1 1 2.1 2 1.9
Nodal status
Negative 206 38.0 16 41.0 13 27.7 40 38.8
Positive 336 62.0 23 59.0 34 72.3 63 61.2
Grading
G1 38 7.0 2 5.1 3 6.4 1 1.0
G2 285 52.6 21 53.8 22 46.8 46 44.7
G3 161 29.7 11 28.2 16 34.0 46 44.7
Unknown 58 10.7 5 12.8 6 12.8 10 9.7
ER status
Negative 215 39.7 12 30.8 22 46.8 69 67.0
Positive 316 58.3 26 66.7 22 46.8 28 27.2
Unknown 11 2.0 1 2.6 3 6.4 6 5.8
PgR status
Negative 250 46.1 18 46.2 26 55.3 72 69.9
Positive 254 46.9 14 35.9 16 34.0 20 19.4
Unknown 38 7.0 7 17.9 5 10.6 11 10.7
ER¼oestrogen receptor; PgR¼progesterone receptor.
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s5-year EFS of 70 and 81%, respectively (HR¼1.64; 95% CI 1.12–
2.40; P¼0.01) (Figure 1A). HER2þ patients had a significantly
shorter OS than HER2  patients, with 23 deaths occurring among
the 103 HER2þ patients as compared to 69 deaths among the
628 HER2  patients for an actuarial 5-year OS of 82 and 91%,
respectively (HR¼2.20; 95% CI 1.37–3.53; P¼0.001) (Figure 1B).
In multivariate analyses, HER2 overexpression was confirmed
to be a factor independently associated with poor EFS (HR¼1.55;
95% CI 1.05–2.28; P¼0.027) and OS (HR¼2.00; 95% CI 1.22–
3.26; P¼0.006). Other adverse prognostic factors associated with
EFS and OS were treatment with FEC21 as compared to FEC14
nodal status, PgR status, proliferative activity, tumour size, and
grading (Tables 3 and 4).
A contralateral breast cancer occurred in 13 cases (three cases in
HER2þ patients and 10 cases in HER2  patients), and in two of
these cases, it was concurrent with loco-regional relapse. The
results of disease-free survival, where the 11 cases of contralateral
breast cancer as first event were excluded, closely mirrored those
of EFS analyses (data not shown).
Interaction between HER-2 overexpression and treatment
Among patients treated with standard FEC21 regimen, both EFS
(HR¼2.07; 95% CI 1.27–3.38; P¼0.003) and OS (HR¼2.47; 95%
CI 1.34–4.57; P¼0.004) were significantly worse in HER2þ than
in HER2  patients (Figure 2A and C). Conversely, among patients
treated with dose-dense FEC14, no statistically significant differ-
ence in either EFS (HR¼1.21; 95% CI 0.65–2.24; P¼0.54) or OS
(HR¼1.85; 95% CI 0.88–3.89; P¼0.103) was observed between
HER2þ and HER2  patients (Figure 2B and D).
Similarly, when the outcomes of patients assigned to FEC14 were
compared to those of patients assigned to FEC21, within the
subgroup of HER2  patients (n¼628), no difference was seen in
EFS (HR¼0.91; 95% CI 0.65–1.27; P¼0.57), whereas, among the
smaller subgroup of HER2þ patients (n¼103), a reduction in the
rate of events was seen in patients assigned to FEC14 (HR¼0.54;
95% CI 0.27–1.11; P¼0.092), although the difference did not reach
statistical significance. When analysing OS, the difference between
the effect of the experimental treatment in HER2  and HER2þ
patients was less marked (HR¼0.79, 95% CI 0.49–1.28, P¼0.34
and HR¼0.59, 95% CI 0.26–1.37, P¼0.22, in HER2  and
HER2þ patients, respectively). Figure 3 shows Kaplan–Meier
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Figure 1 Event-free survival (A) and OS (B) curves of HER2-positive
(HER2þ) vs HER2-negative (HER2 ) patients.
Table 3 Multivariate analysis – effect of various prognostic factors on EFS
Factor strata No. of patients Events HR 95% CI P
Random
FEC21 361 92 1 (ref)
FEC14 370 78 0.75 0.55–1.02 0.067
Age (years)
o50 262 55 —
50–59 253 59 —
459 216 56 — 0.68
a
Menopausal status
Pre 293 61 —
Post 438 109 — 0.469
a
Nodal status
N  275 33 1 (ref)
N+ 456 137 3.37 2.28–5.00 o0.0001
Grading
14 4 5 —
2 374 79 —
3 234 66 —
Unknown 79 20 — 0.23
a
ER status
Negative 318 82 —
Positive 392 81 —
Unknown 21 7 — 0.81
a
PgR status
Negative 366 101 1 (ref)
Positive 304 57 0.58 0.41–0.81
Unknown 61 12 0.54 0.29–0.98 0.002
Proliferative activity
Low 189 31 1 (ref)
High 263 69 2.11 1.36–3.25
Unknown 279 70 1.80 1.17–2.76 0.003
Tumour size
pT1 344 61 1 (ref)
PT2/3/4/unknown 387 109 1.74 1.27–2.387 0.01
HER2
Negative 628 137 1 (ref)
Positive 103 33 1.55 1.05–2.28 0.027
EFS¼event-free survival; ER¼oestrogen receptor; PgR¼progesterone receptor.
aRemoved from the final model.
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splots for EFS and OS. In HER2  patients, EFS at 5 years was 80.9%
(95% CI 76.3–85.5%) and 81.5% (95% CI 76.9–86.0%) in FEC21
and FEC14, respectively, and OS at 5 years was 90.7% (95% CI
87.4–94.0%) and 91.9% (95% CI 88.9–94.9%) in FEC21 and
FEC14, respectively. In contrast, for HER2þ patients, Kaplan–
Meier estimates of 5-year EFS were 62.5% (95% CI 49.0–75.9%) in
FEC21 vs 77.7% (95% CI 65.5–89.9%) in FEC14 arms, and 5-year
estimates of OS were 75.1% (95% CI 63.5–86.9%) in FEC21 vs
89.9% (95% CI 81.6–98.3%) in FEC14 arms.
When the potential modifying role of HER2 status on the effect
of the experimental treatment was formally assessed by introdu-
cing the appropriate interaction term in the two multivariate
models (one for EFS, the other for OS), the results were suggestive
but not statistically significant for EFS (P for interaction¼0.12),
and negative for OS (P for interaction¼0.379).
In both models, however, the estimated coefficients suggested
that the use of dose-dense adjuvant chemotherapy might remove
the negative prognostic effect of HER2 overexpression on EFS and
partially contrasted that on OS (Table 5).
DISCUSSION
We evaluated both the prognostic role of HER2 overexpression
and its potential role as a modifier of the effect of adjuvant therapy
in a population of early breast cancer patients enrolled in a phase
III study comparing two epirubicin-containing regimens with
different dose densities. In the overall population, regardless of
the FEC regimen received (dose dense or standard), HER2 over-
expression was associated with a poor prognosis. Both EFS
(HR¼1.64; 95% CI 1.12–2.40) and OS (HR¼2.2; 95% CI 1.37–
3.53) were significantly shorter in HER2þ patients than in HER2 
patients. Because all patients in our study were treated with FEC
chemotherapy, our results indicate that HER2 overexpression
retains its prognostic role also in patients receiving anthracycline-
containing chemotherapy.
The role of HER2 in predicting sensitivity to anthracyclines is
still under investigation. Clinical data suggest that women whose
tumours overexpress HER2 might derive greater benefit from
anthracycline-based than from alkylating agent-based adjuvant
Table 4 Multivariate analysis – effect of various prognostic factors on OS
Factor strata No. of patients Events HR 95% CI P
Random
FEC21 361 52 1 (ref)
FEC14 370 40 0.65 0.43–0.98 0.041
Age (years)
o50 262 27 —
50–59 253 34 — —
459 216 31 — — 0.600
a
Menopausal status
Pre 293 31 —
Post 438 61 — 0.246
a
Nodal status
N  275 14 1 (ref)
N+ 456 78 4.34 2.42–7.77 o0.0001
Grading
1 44 4 1 (ref)
2 374 36 0.85 0.30–2.42
3 234 39 1.30 0.45–3.77
Unknown 79 13 1.77 0.57–5.51 0.038
ER status
Negative 318 52 —
Positive 392 35 —
Unknown 21 5 — 0.68
a
PgR status
Negative 366 61 1 (ref)
Positive 304 26 0.49 0.31–0.79
Unknown 61 5 0.31 0.12–0.80 0.001
Proliferative activity
Low 189 15 1 (ref)
High 263 36 2.20 1.19–4.08
Unknown 279 41 2.02 1.11–3.67 0.02
Tumour size
PT1 344 24 1 (ref)
PT2/3/4/unknown 387 68 2.52 1.58–4.02 o0.0001
HER2
Negative 628 69 1 (ref)
Positive 103 23 2.00 1.22–3.26 0.006
OS¼overall survival; ER¼oestrogen receptor; PgR¼progesterone receptor.
aRemoved from the final model.
HER2 and dose-density chemotherapy
L Del Mastro et al
11
British Journal of Cancer (2005) 93(1), 7–14 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stherapy (Paik et al, 1998, 2000; Di Leo et al, 2002). Another
clinically important issue is whether HER2 overexpression or
amplification is predictive of the benefit deriving from the use of
anthracyclines administered at a dose intensity and/or dose
density higher than the standard dose. Two retrospective studies
addressed the issue of the potential association between HER2 and
the increased dose intensity of anthracycline-containing chemo-
therapy. In both studies, the increase in dose intensity was
obtained by increasing the single dose per cycle while intervals
between cycles were not reduced, that is, the dose density was not
increased (Thor et al, 1998; Di Leo et al, 2002). Results from
CALGB 8541 study, in which patients were randomised to three
different dose levels of CAF, suggest that the benefit from the
higher dose-intensity CAF was confined to women with HER2
overexpression. However, the dose level defined as higher is
what we now consider the standard dose, that is, 60mgm
 2
of doxorubicin. The study from Piccart et al (2001) compared
two regimens of epirubicin at different dose intensities (60 vs
100mgm
 2 per cycle) with CMF (Piccart et al, 2001). A
retrospective analysis carried out in 55% of the clinical trial
population showed no difference in EFS between high dose-
intensity and standard dose-intensity epirubicin in the small group
of HER2-amplified patients. The results of the two above-cited
studies indicate that the potential association between HER2
overexpression or amplification and anthracycline dose-intensity
benefit remains to be clarified.
This study, to the best of our knowledge, is the first to
investigate the potential role of HER2 in predicting the efficacy of a
dose-dense epirubicin-containing adjuvant chemotherapy. In our
study, patients received the same drug doses per cycle and the
same total dose in the two arms, and the only difference between
the two arms was the interval between cycles, that is, 2-week (dose
dense) vs 3-week (standard) schedule. Our results suggest that
dose-dense FEC14 may be superior to FEC21 in HER2þ patients
only, even though differences in outcome did not reach statistical
significance. In the HER2þ cohort, the relative risks of failure for
FEC14-treated patients as compared to FEC21 were 0.54 (95% CI
0.27–1.11; P¼0.092) for EFS and 0.59 (95% CI 0.26–1.37;
P¼0.22) for survival. In HER2þ patients, treatment with FEC14
was associated with 15.2% (95% CI  3–33.4%) and 14.8% (95% CI
0.4–29.2%) absolute increase in 5-year EFS and OS, respectively,
as compared to HER2þ patients receiving FEC21. Among patients
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Figure 2 Event-free survival and OS curves of HER2-positive (HER2þ) vs HER2-negative (HER2 ) patients according to FEC21 (A–C) or dose-dense
FEC14 (B–D) treatment.
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streated with FEC21 regimen, both EFS and OS were shorter in
HER2þ patients than in HER2  patients, while when patients
were treated with dose-dense FEC14, differences in outcome
between HER2þ and HER2  patients were not statistically
significant.
The potential higher efficacy of dose-dense FEC14 treatment in
HER2þ patients than in HER2  patients may be biologically
explained by data suggesting that HER2 overexpression confers a
high proliferative capability to the tumour (Borg et al, 1991) and is
associated with an amplification of topoisomerase II alpha gene, a
potential marker of anthracycline sensitivity (Di Leo et al, 2002).
Because the regrowth of cancer cells between cycles of cytoreduc-
tion is likely to be more rapid in HER2þ tumours, the more
frequent administration of anthracycline-containing chemother-
apy could be particularly effective in these anthracycline-sensitive
tumours.
These results suggest a potential role of HER2 overexpression
in predicting the efficacy of dose-dense epirubicin-containing
adjuvant chemotherapy, but they must be considered with caution
because of some weaknesses of the study. The first one is related to
its retrospective nature. Even though no remarkable difference was
seen between patients included and those not included in the
present study, the possibility of a selection bias cannot be ruled
out. The second limitation is due to its statistical power, and
specifically to the small number of HER2-positive patients. As a
matter of fact, with 170 events and 92 deaths, the study had limited
power (o30%) in detecting plausible differences (HR between 1.25
and 1.33) in the risk of relapse and of death, particularly in
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Figure 3 Event-free survival (A, B) and OS (C–D) curves of FEC21-treated patients vs dose-dense FEC14-treated patients according to HER2 status.
Table 5 Results of interaction analyses
Factor Coefficient (s.e.) HR P
EFS
a
Random (FEC14 vs FEC21)  0.166 (0.173) 0.85 0.335
HER2 status (positive vs negative) 0.713 (0.254) 2.04 0.005
Random HER2 status  0.633 (0.405) 0.53 0.118
OS
a
Random (FEC14 vs FEC21)  0.328 (0.245) 0.72 0.180
HER2 status (positive vs negative) 0.881 (0.321) 2.41 0.006
Random HER 2 status  0.438 (0.497) 0.646 0.379
EFS¼event-free survival; OS¼overall survival.
aEstimates obtained from a model
with nodal status, PgR status, proliferative index (low, high, unknown), and pT (pT1 vs
greater).
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sinteraction analyses. As a consequence, some of the observed
differences fail to achieve statistical significance. A third possible
limitation is the absence of FISH testing. When our study started,
at the end of 1998, FISH testing on paraffin-embedded specimens
was not widely available. Then, we performed our analysis using
immunohistochemistry. At that time, CB11 was among the most
commonly primary reagents used to determine HER2 status.
Moreover, the hypothesis of an interaction between anthracycline
dose intensity and HER2 overexpression was tested just by using
CB11 (Thor et al, 1998).
Eventually, as expected, HER2 overexpression was inversely
associated with the expression of hormone receptors (Table 2),
leading to a more frequent use of endocrine therapy in HER2-
negative patients than in HER2-positive patients. This different use
of endocrine therapy may potentially confound the outcome.
However, our results were obtained from multivariate analysis
where the potential confounding effect of hormonal status and the
consequent endocrine therapy was accounted for.
Owing to these limitations, our results should be considered
exploratory and need to be confirmed in prospective, well-powered
studies.
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